Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success
Hatteras Venture Partners has secured more than $200 million across two new funds aimed at early-stage biotechs, medtech, and healthcare startups12.
The capital is split between Hatteras Venture Fund VII and Hatteras Opportunity Fund I1.
This fundraising follows a successful exit from HistoSonics, marking a significant achievement for the firm1.
Hatteras recently invested in its 100th portfolio company, highlighting continued growth and commitment to life sciences innovation1.
The firm has raised over $900 million in its 25-year history, supporting seed and early-stage health innovation companies in the U.S., particularly in biotech, medtech, and healthtech sectors1.
Recent portfolio highlights include Kymera Therapeutics, which Hatteras supported in a $65 million Series B funding round; Kymera has since gained partnerships with major pharma companies like Sanofi and Gilead1.
Sources:
1. https://www.fiercebiotech.com/biotech/vc-firm-hatteras-handles-200m-across-2-funds-aimed-early-stage-life-sciences-startups